Is CRON or AMRN more profitable?

Cronos Group has a net margin of 39.08% compared to Amarin's net margin of -14.56%. Cronos Group's return on equity of 4.85% beat Amarin's return on equity. Company Net Margins Return on Equity Return on Assets Cronos Group 39.08% 4.85% 4.62% Amarin -14.56% -0.20% -0.14%

Does the media refer more to CRON or AMRN?

In the previous week, Cronos Group had 1 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Cronos Group and 6 mentions for Amarin. Cronos Group's average media sentiment score of 1.10 beat Amarin's score of 0.52 indicating that Cronos Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ANRO or AMRN?

In the previous week, Alto Neuroscience had 4 more articles in the media than Amarin. MarketBeat recorded 10 mentions for Alto Neuroscience and 6 mentions for Amarin. Alto Neuroscience's average media sentiment score of 0.77 beat Amarin's score of 0.52 indicating that Alto Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ARDX or AMRN?

Amarin has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ardelyx $407.32M 2.33 -$61.60M -$0.22 N/A Amarin $186.23M 1.58 -$38.80M -$0.99 N/A

Is ARDX or AMRN more profitable?

Ardelyx has a net margin of -12.35% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -12.35% -36.00% -10.77% Amarin -14.56% -0.20% -0.14%

Does the media favor ARDX or AMRN?

In the previous week, Ardelyx had 20 more articles in the media than Amarin. MarketBeat recorded 26 mentions for Ardelyx and 6 mentions for Amarin. Ardelyx's average media sentiment score of 0.61 beat Amarin's score of 0.52 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, IVA or AMRN?

Amarin has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $4.48M 217.76 -$400.67M N/A N/A Amarin $186.23M 1.58 -$38.80M -$0.99 N/A

Is IVA or AMRN more profitable?

Inventiva has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Inventiva's return on equity of 0.00% beat Amarin's return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Amarin -14.56% -0.20% -0.14%

Does the media favor COLL or AMRN?

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than Amarin. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 6 mentions for Amarin. Collegium Pharmaceutical's average media sentiment score of 1.09 beat Amarin's score of 0.52 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amarin (AMRN) Competitors

$13.97 -0.10 (-0.71%)

As of 08/28/2026 04:00 PM Eastern

Compare

AMRN vs. CRON, ANRO, ARDX, IVA, and COLL

Should you buy Amarin stock or one of its competitors? Amarin's main competitors and comparable companies include Cronos Group (CRON), Alto Neuroscience (ANRO), Ardelyx (ARDX), Inventiva (IVA), and Collegium Pharmaceutical (COLL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Amarin compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 7.8% of Cronos Group shares are held by company insiders. Comparatively, 4.2% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cronos Group has a net margin of 39.08% compared to Amarin's net margin of -14.56%. Cronos Group's return on equity of 4.85% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Amarin	-14.56%	-0.20%	-0.14%

Cronos Group presently has a consensus price target of $2.30, suggesting a potential downside of 31.95%. Amarin has a consensus price target of $13.00, suggesting a potential downside of 6.94%. Given Amarin's higher possible upside, analysts plainly believe Amarin is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Cronos Group has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Amarin has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Cronos Group has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$179.09M	7.00	-$9.45M	$0.20	16.90
Amarin	$186.23M	1.58	-$38.80M	-$0.99	N/A

In the previous week, Cronos Group had 1 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Cronos Group and 6 mentions for Amarin. Cronos Group's average media sentiment score of 1.10 beat Amarin's score of 0.52 indicating that Cronos Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cronos Group beats Amarin on 13 of the 16 factors compared between the two stocks.

How does Amarin compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Alto Neuroscience has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-46.46%	-39.09%
Amarin	-14.56%	-0.20%	-0.14%

Alto Neuroscience currently has a consensus price target of $37.25, indicating a potential upside of 6.03%. Amarin has a consensus price target of $13.00, indicating a potential downside of 6.94%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, analysts clearly believe Alto Neuroscience is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

In the previous week, Alto Neuroscience had 4 more articles in the media than Amarin. MarketBeat recorded 10 mentions for Alto Neuroscience and 6 mentions for Amarin. Alto Neuroscience's average media sentiment score of 0.77 beat Amarin's score of 0.52 indicating that Alto Neuroscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.3% of Amarin shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Amarin has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Amarin	$186.23M	1.58	-$38.80M	-$0.99	N/A

Alto Neuroscience has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Amarin has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Summary

Alto Neuroscience beats Amarin on 8 of the 15 factors compared between the two stocks.

How does Amarin compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Ardelyx has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Amarin has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 5.3% of Ardelyx shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ardelyx has a net margin of -12.35% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-36.00%	-10.77%
Amarin	-14.56%	-0.20%	-0.14%

Amarin has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	2.33	-$61.60M	-$0.22	N/A
Amarin	$186.23M	1.58	-$38.80M	-$0.99	N/A

In the previous week, Ardelyx had 20 more articles in the media than Amarin. MarketBeat recorded 26 mentions for Ardelyx and 6 mentions for Amarin. Ardelyx's average media sentiment score of 0.61 beat Amarin's score of 0.52 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx currently has a consensus target price of $13.90, indicating a potential upside of 264.83%. Amarin has a consensus target price of $13.00, indicating a potential downside of 6.94%. Given Ardelyx's stronger consensus rating and higher probable upside, equities analysts plainly believe Ardelyx is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Summary

Ardelyx beats Amarin on 12 of the 17 factors compared between the two stocks.

How does Amarin compare to Inventiva?

Inventiva (NASDAQ:IVA) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

19.1% of Inventiva shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Inventiva has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Inventiva's return on equity of 0.00% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Amarin	-14.56%	-0.20%	-0.14%

Inventiva currently has a consensus price target of $15.38, indicating a potential upside of 227.13%. Amarin has a consensus price target of $13.00, indicating a potential downside of 6.94%. Given Inventiva's stronger consensus rating and higher probable upside, equities analysts plainly believe Inventiva is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

In the previous week, Amarin had 5 more articles in the media than Inventiva. MarketBeat recorded 6 mentions for Amarin and 1 mentions for Inventiva. Inventiva's average media sentiment score of 1.87 beat Amarin's score of 0.52 indicating that Inventiva is being referred to more favorably in the media.

Company	Overall Sentiment
Inventiva	Very Positive
Amarin	Positive

Inventiva has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Amarin has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Amarin has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$4.48M	217.76	-$400.67M	N/A	N/A
Amarin	$186.23M	1.58	-$38.80M	-$0.99	N/A

Summary

Inventiva beats Amarin on 10 of the 15 factors compared between the two stocks.

How does Amarin compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than Amarin. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 6 mentions for Amarin. Collegium Pharmaceutical's average media sentiment score of 1.09 beat Amarin's score of 0.52 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Collegium Pharmaceutical has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$808.21M	1.02	$62.87M	$1.24	20.44
Amarin	$186.23M	1.58	-$38.80M	-$0.99	N/A

Collegium Pharmaceutical presently has a consensus target price of $51.00, indicating a potential upside of 101.18%. Amarin has a consensus target price of $13.00, indicating a potential downside of 6.94%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Collegium Pharmaceutical is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

22.3% of Amarin shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Amarin has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 5.93% compared to Amarin's net margin of -14.56%. Collegium Pharmaceutical's return on equity of 91.43% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Amarin	-14.56%	-0.20%	-0.14%

Summary

Collegium Pharmaceutical beats Amarin on 13 of the 17 factors compared between the two stocks.

Get Amarin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRN vs. The Competition

Export

Metric	Amarin	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$295.09M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-14.11	787.65	273.16	25.45
Price / Sales	1.58	793.10	605.06	76.64
Price / Cash	38.70	91.95	76.74	53.00
Price / Book	0.67	11.97	12.98	6.14
Net Income	-$38.80M	$2.83B	$3.48B	$348.86M
7 Day Performance	-0.85%	0.39%	0.13%	-0.80%
1 Month Performance	-1.83%	5.34%	7.08%	4.13%
1 Year Performance	-7.11%	6.05%	24.67%	15.17%

Amarin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRN Amarin	0.8984 of 5 stars	$13.97 -0.7%	$13.00 -6.9%	-7.1%	$295.09M	$186.23M	N/A	360	News Coverage
CRON Cronos Group	1.9316 of 5 stars	$3.15 +0.3%	$2.30 -27.0%	+30.0%	$1.16B	$179.09M	15.75	450	Positive News Analyst Upgrade Options Volume
ANRO Alto Neuroscience	1.4519 of 5 stars	$33.70 +4.9%	$37.25 +10.5%	+848.2%	$1.13B	N/A	N/A	N/A	News Coverage Analyst Upgrade Gap Down
ARDX Ardelyx	4.0196 of 5 stars	$4.06 flat	$14.90 +267.0%	-40.1%	$1.01B	$407.32M	N/A	90	Insider Trade Options Volume
IVA Inventiva	2.6377 of 5 stars	$4.70 +2.2%	$16.56 +252.2%	-24.1%	$955.45M	$5.07M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRN) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amarin (AMRN) Competitors